MetaVia is trading 11.16% up at $1.70, with no clearly reported catalyst identified for August 25, 2026.

  • The latest major corporate update was the August 6, 2026 second-quarter report, which discussed progress for DA-1726 and vanoglipel.
  • Broader markets are modestly higher, but available index gains remain below the 0.5% threshold for attributing this move to market sentiment.